PCSK9 and coronary artery disorder: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to reduce Lp(a) levels by 20-25 % [49], which accounted for 3.8 % of the total beneficial effects of PCSK9 inhibitors on the risk of CAD [50].